Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC).

Kohli M, Wang L, Tan AC, Fadlullah MZ, Shankar A, Mandrekar SJ, Haaland B

Open source

DOI: 10.1016/j.jlb.2026.100486
Published: 2026 Sep
Container: The journal of liquid biopsy
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jlb.2026.100486,
  title = {Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC).},
  author = {Kohli M and Wang L and Tan AC and Fadlullah MZ and Shankar A and Mandrekar SJ and Haaland B},
  year = {2026},
  journal = {The journal of liquid biopsy},
  doi = {10.1016/j.jlb.2026.100486},
  url = {https://doi.org/10.1016/j.jlb.2026.100486}
}

RIS

TY  - JOUR
TI  - Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC).
AU  - Kohli M
AU  - Wang L
AU  - Tan AC
AU  - Fadlullah MZ
AU  - Shankar A
AU  - Mandrekar SJ
AU  - Haaland B
PY  - 2026
JO  - The journal of liquid biopsy
DO  - 10.1016/j.jlb.2026.100486
UR  - https://doi.org/10.1016/j.jlb.2026.100486
ER  -

APA

M, K., L, W., AC, T., MZ, F., A, S., SJ, M., & B, H. (2026). Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC).. The journal of liquid biopsy. https://doi.org/10.1016/j.jlb.2026.100486

Source records

pubmed · retrieved 2026-09-25T13:24:56.792Z
europe-pmc · retrieved 2026-09-25T13:24:56.807Z
doaj · retrieved 2026-09-25T13:24:56.812Z